A Four-way Crossover, Single and Repeat Dose Study to Determine the Dose Proportionality and Absolute Bioavailability of Fluticasone Furoate Inhalation Powder Administered by Novel Dry Powder Inhaler (NDPI)

NCT01669070 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

DRUG: FF, 50 mcg
DRUG: FF, 100 mcg
DRUG: FF, 200 mcg
DRUG: FF, 250 mcg

Sponsor

GlaxoSmithKline